SCHEMBL14729097

SCHEMBL14729097

CS(=O)(=O)c1ccc(-c2ccc3nc(OC4CCN(C(=O)C5CC5)CC4)sc3c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
TP53 P04637 3/20 0.45
LMNA P02545 3/20 0.45
CLK1 P49759 1/20 0.44
GPR119 Q8TDV5 10/20 0.44
JAK3 P52333 1/20 0.41
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RECQL P46063 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PIK3CD O00329 2/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PI4KA P42356 1/20 0.40
PIK3CG P48736 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
BRD4 O60885 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14729100 0.90 IKBKB (0.44) LMNACLK1GPR119JAK3USP2
SCHEMBL2591259 0.90 GPR119 (0.43) LMNACLK1GPR119JAK3USP2
SCHEMBL14729201 0.90 CLK1 (0.41) LMNACLK1GPR119JAK3USP2
SCHEMBL14729093 0.89 GPR119 (0.47) LMNACLK1GPR119JAK3USP2
SCHEMBL14729195 0.87 GPR119 (0.41) LMNACLK1GPR119JAK3USP2
SCHEMBL2583595 0.87 GPR119 (0.58) GPR119
SCHEMBL14729099 0.86 LIPC (0.45) MAPTLMNAGPR119ALDH1A1
SCHEMBL14729197 0.86 GPR119 (0.41) LMNACLK1GPR119JAK3USP2
SCHEMBL14729095 0.85 GPR119 (0.48) CLK1GPR119ALDH1A1PIK3CD
SCHEMBL14729103 0.85 PIK3CD (0.41) LMNACLK1GPR119USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
EP-2566860-B1 BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2014-09-10 EP disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS GPR119, GPR139, GPR4 MAPT 1165/4885TP53 4228/4885LMNA 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.